Braveheart Bio, Inc. filed a Form 8-K on November 6, 2026, disclosing that the company and Hengrui Pharma presented data from a 52-week open-label extension of a Phase 2 study of HRS/BHB-1893 in obstructive hypertrophic cardiomyopathy at the American Heart Association Scientific Sessions 2026.

Key Highlights

  • Data presentation: Hengrui Pharma and Braveheart Bio presented results from a 52-week open-label extension of a Phase 2 study of HRS/BHB-1893 in obstructive hypertrophic cardiomyopathy.
  • Venue: The data were presented at the American Heart Association Scientific Sessions 2026.
  • Disclosure date: The press release was issued on November 6, 2026.
  • Exchange listing: Braveheart Bio common stock (par value $0.0001 per share) trades on The Nasdaq Global Market under the symbol BRVE, as stated on NASDAQ:BRVE.
  • Regulatory classification: The filing was made under Item 7.01 (Regulation FD Disclosure) and the information is furnished, not filed, for purposes of Section 18 of the Securities Exchange Act of 1934.
  • Emerging growth company: The registrant indicated it qualifies as an emerging growth company under applicable SEC rules.

Braveheart Bio and Hengrui Pharma Share HRS/BHB-1893 Extension Study Findings

According to the filing, Braveheart Bio, Inc. issued a press release on November 6, 2026, announcing that the company and its partner Hengrui Pharma presented data from the 52-week open-label extension phase of a Phase 2 clinical study of HRS/BHB-1893. The study focuses on obstructive hypertrophic cardiomyopathy, a condition affecting the heart muscle. The presentation took place at the American Heart Association Scientific Sessions 2026.

The 8-K was filed under Item 7.01, Regulation FD Disclosure. The filing states that the information furnished, including the accompanying press release (Exhibit 99.1), "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended," and is not automatically incorporated by reference into other filings unless expressly specified. The underlying press release is attached as Exhibit 99.1 and incorporated by reference into the Current Report.

Braveheart Bio is a Delaware-incorporated company headquartered at One Letterman Drive, Building A, Suite A4-300, San Francisco, CA 94129. The filing was signed by J. Paul Rickey, Chief Financial Officer, on November 6, 2026. The company's common stock, par value $0.0001 per share, is registered under Section 12(b) of the Securities Exchange Act on The Nasdaq Global Market under the ticker symbol BRVE.

What Was Disclosed

Braveheart Bio filed an 8-K on November 6, 2026, to disclose under Regulation FD that it and Hengrui Pharma presented 52-week open-label extension data from a Phase 2 study of HRS/BHB-1893 in obstructive hypertrophic cardiomyopathy at the American Heart Association Scientific Sessions 2026.